In Situ Hybridization Market Seen Reaching $3.08 Billion by 2030

The global in situ hybridization market is forecast to grow from $1.81 billion in 2025 to $2.01 billion in 2026, driven by cancer diagnostics, molecular pathology research and infectious disease testing. The Business Research Company says the market could climb to $3.08 billion by 2030 as fluorescence-based methods, AI image analysis and companion diagnostics gain traction.

Why it matters: - In situ hybridization is becoming more central to molecular diagnostics, especially for cancer and infectious disease testing. - The market’s projected growth signals rising demand for more precise tissue-level analysis in research and clinical settings. - Faster adoption could affect labs, diagnostics providers and drug developers using companion diagnostics and genomic tools.

What happened: - The Business Research Company published its In Situ Hybridization Global Market Report 2026 with estimates for 2026 through 2035. - The report puts the market at $1.81 billion in 2025 and $2.01 billion in 2026. - The report forecasts the market will reach $3.08 billion by 2030. - The report was released in London on Aug. 12, 2026. - The full report is available here. - A free sample is available here.

The details: - In situ hybridization is a laboratory technique used to localize specific nucleic acid sequences within histologic sections. - The method is used to detect targeted nucleotide segments in whole tissues, tissue sections and individual cells. - The market’s 2025-2026 growth is tied to molecular pathology research, cancer diagnostics, cytogenetic testing, better laboratory infrastructure and wider use of fluorescence in situ hybridization, or FISH. - The longer-term forecast reflects demand for personalized medicine diagnostics, AI-driven image analysis, companion diagnostics, genomic studies and infectious disease detection. - The report highlights a shift toward fluorescence-based hybridization methods, more accurate molecular diagnostics, increased imaging automation, broader cancer diagnostic use and deeper digital pathology integration. - Rising infectious disease prevalence is supporting demand for the technology. - The report cites CDC data showing U.S. tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023.

Between the lines: - The report points to a market moving beyond basic tissue analysis toward more automated and data-rich diagnostic workflows. - AI image analysis and digital pathology are likely to matter because they can speed interpretation and reduce manual review in high-volume labs. - Infectious disease testing adds another growth lane beyond oncology, which could broaden the market’s customer base.

What's next: - The Business Research Company expects the market to keep expanding at an 11.3% CAGR through 2030. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - North America held the largest market share in 2025. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - New report features include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables.

The bottom line: - In situ hybridization is shifting from a niche lab method to a broader diagnostic platform, with oncology, infectious disease testing and digital pathology driving the next phase of growth.